June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Photodynamic Therapy vs Combination Therapy in Polypoidal Choroidal Vasculopathy: Changes of Aqueous Vascular Endothelial Growth Factor
Author Affiliations & Notes
  • Meeyon Lee
    Chung ang University hospital, Seoul, Republic of Korea
  • Won Ki Lee
    Seoul St. Mary hospital, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships Meeyon Lee, None; Won Ki Lee, Novartis (F), Novartis (C), Bayer (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4507. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Meeyon Lee, Won Ki Lee; Photodynamic Therapy vs Combination Therapy in Polypoidal Choroidal Vasculopathy: Changes of Aqueous Vascular Endothelial Growth Factor. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4507.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To investigate the influence of photodynamic therapy (PDT) and combination of PDT and ranibizumab on aqueous humor levels of vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV).

Methods: Prospective, randomized clinical trial. We included twenty eyes with treatment-naïve PCV and 20 eyes undergoing cataract surgery as controls. Eyes with PCV were randomized to treatment with PDT alone or to a combination of ranibizumab and PDT on same day. During 3 months of follow-up, retreatment was not performed. Aqueous humor samples were collected at baseline and at 1 week, 1 month and 3 months after treatment in PCV group and during cataract surgery in the control group. VEGF levels were measured using multiplex bead immunoassay.

Results: At baseline, concentrations of VEGF were significantly increased in PCV eyes compared with control eyes. A significant decrease in VEGF levels were found at 1 week after PDT treatment (n=8), and at all time points after combination treatment (n=12). With combination treatment, VEGF levels were decreased to values below the detection limit in all eyes at 1 week and 1 month, and in 7 of 12 eyes at 3 months.

Conclusions: Decreased levels of VEGF detected 1 week after PDT for PCV seems to reflect acute damage of vascular endothelial cells, one of VEGF expression sites. Concomitant ranibizumab resulted in a further decrease in VEGF expression to negligible levels. This effect persisted for at least 1 month and as long as 3 months in more than half of the cases.

Keywords: 688 retina • 412 age-related macular degeneration • 748 vascular endothelial growth factor  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.